January 10, 2019 / 9:13 AM / 5 months ago

BRIEF-Novartis Responds To NICE Appraisal Consultation For Migraine Drug

Jan 10 (Reuters) - Novartis UK:

* NOVARTIS RESPONSE TO NICE APPRAISAL CONSULTATION DOCUMENT (ACD) FOR AIMOVIG (ERENUMAB) FOR THE PREVENTION OF MIGRAINE

* DISAPPOINTED BY DECISION FROM NICE TO NOT RECOMMEND AIMOVIG FOR ROUTINE USE ON NHS, YET WELCOME OPPORTUNITY FOR FURTHER DISCUSSION Source text 0 (bit.ly/2RHuOZh) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below